Skip to main content
. 2014 Apr 10;9(4):e94561. doi: 10.1371/journal.pone.0094561

Figure 2. Evaluation of the inhibitory effects of the peptide-fusion protein and the individual antiviral peptides against dengue NS2B-NS3 protease.

Figure 2

Recombinant dengue NS2B-NS3pro was produce in E. coli and used in an end point reaction mixture with fluorogenic peptide substrate, antiviral peptides of varying concentrations and buffer. The antiviral peptides showed significant dose-dependent inhibition towards dengue NS2B-NS3pro. The peptide-fusion protein inhibited dengue protease at IC50 value lower than MAP30, PG1 and PLSN.